Abstract
The introduction of angiotensin-converting enzyme (ACE) inhibitors for the treatment of hypertension and heart failure is probably the most important advance in cardiovascular pharmacotherapy in the last few decades. Although the role of the renin-angiotensin system (RAS) in cardiovascular diseases had been investigated extensively for more than 70 yr, the therapeutic application of this knowledge became possible only after the introduction of a practical way to block this system. It is now well established that activation of the RAS has a detrimental effect on the cardiovascular system and promotes arterial, myocardial, and renal damage. ACE inhibition was shown to diminish morbidity and mortality in patients with ischemic cardiomyopathy after myocardial infarction (MI), in patients with left ventricular impairment ranging from subclinical diastolic dysfunction to advanced systolic dysfunction with decompensated congestive heart failure (CHF), and in patients with diabetic nephropathy. Accordingly, these conditions are now compelling indications for treatment with ACE inhibitors (1), even in non-hypertensive patients.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
The Sixth Report of the joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (1997) Arch Intern Med 157: 2413–2446.
Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA (1974) An angiotensin converting enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 291: 817–821.
Erdos EG (1975) Angiotensin I converting enzyme. Circ Res 36: 247–255.
Gavras H, Liang C, Brunner HR (1978) Redistribution of regional blood flow after inhibition of the angiotensin converting enzyme. Circ Res 43 (Suppl. 1): 59–63.
Faxon DP, Creager MA, Halperin JL, Gavras H, Coffman JD, Ryan TJ (1980) Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failure. Circulation 61: 925–931.
Dostal DE, Baker KM (1995) Biochemistry, molecular biology, and potential roles of the cardiac renin—angiotensin system. In Dhalla NS, Takeda N, Nagano M, eds. The Failing Heart, Philadelphia: Lippincott-Raven, pp. 275–294.
Regoli D, Rhaleb NE, Drapeau G, et al. (1989) Basic pharmacology of kinin: pharmacologic receptors and other mechanisms. In: Abe K, Moriya F, Fuji S, eds. Kinins V, Plenum NY, pp. 398–407.
Kohlman O Jr, De Assis Rocha Neves F, Ginoza M, Tavares A, Cezaretti ML, Zanella MT, Ribeiro AB, Gavras I, Gavras H (1995) Role of bradykinin in insulin sensitivity and blood pressure regulation during hyperinsulinemia. Hypertension 25: 1003–1007.
Gavras I (1992) Bradykinin-mediated effects of ACE inhibition. Kidney Int 42: 1020–1029.
Israili ZH, Hall WD (1992) Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med 117: 234–342.
Mulinari R, Gavras I, Gavras H (1987) Efficacy and tolerability of enalapril monotherapy in mild-to-moderate hypertension in older patients compared to younger patients. Clin Ther 9 (6): 678–692.
Anderson S, Rennke HG, Brenner BM (1986) Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993–2000.
The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: result of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435.
The SOLVD Investigators. (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685–691.
Cohn JN, Johnson G, Ziesche S, et al. (1991) A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303–310.
Sharpe N, Murphy J, Smith H, Hannan S (1988) Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1: 255–259.
Pfeffer MA, Lamas GA, Vaughan DE, Paris AF, Braunwald E (1988) Effect of captopril on progressive ventricular dilation after anterior myocardial infarction. N Engl J Med 319: 80–86.
Pfeffer MA, Braunwald E, Moye LA, et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 327: 669–677.
The AIRE Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342: 821–828.
Clark CM Jr, Lee DA (1995) Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 332: 1210–1217.
The GISEN Group (1997) Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in protein-uric, non-diabetic nephropathy. Lancet 349: 1857–1863.
Yusuf S, Pepine CJ, Garces C, et al. (1992) Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340: 1173–1178.
Estacio RO, Jeffers BW, Hiatt WR, Biggi SL, Gifford N, Schrier RW (1998) The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with non-insulin-dependent diabetes and hypertension. NEngl JMed 338: 645–652.
Tatti P, Pahor M, Byington RP, DiMauro P, Guarisco R, Strollo F (1997) Results of the Fosinopril Amlodipine Cardiovascular Events Trial (FACET) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM). Circulation 96 (Suppl. I): I-764 (abstract).
Byington RP, Craven T, Furberg CD, Pahor M (1997) Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet 350: 1075, 1076.
Kostis JB (1995) The effect of enalapril on mortal and morbid events in patients with hypertension and left ventricular dysfunction. Am J Hypertens 8: 909–914.
MacMahon SW, Cutler JA, Furberg CD, et al. (1986) The effects of drug treatment for hypertension morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Progr Cardiovasc Dis 29 (Suppl. I): 99–118.
Cavis BR, Cutler JA, Gordon DJ, et al. (1996) Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). Am J Hypertens 9: 342–360.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gavras, I., Gavras, H. (2001). Angiotensin-Converting Enzyme Inhibitors. In: Weber, M.A. (eds) Hypertension Medicine. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-008-7_28
Download citation
DOI: https://doi.org/10.1007/978-1-59259-008-7_28
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4757-5446-9
Online ISBN: 978-1-59259-008-7
eBook Packages: Springer Book Archive